disappointing preliminary results for a phase three trial of a lung cancer treatment.
AstraZeneca said it slowed progression of the cancer, but the data for overall survival was "not mature" and the results were not statistically significant. The trial will continue to assess overall survival with greater maturity, the company said.
We have summarized this news so that you can read it quickly. If you are interested in the news, you can read the full text here. Read more:
Coin Coin Latest News, Coin Coin Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
Source: CNBC - 🏆 12. / 72 Read more »